Substituted Pyrazolo[1,5-a]pyrimidine-7-amine CDK Inhibitor Compounds and Therapeutic Use

EPO published a new patent application (EP4355426A1) by Carrick Therapeutics Limited for substituted pyrazolo[1,5-a]pyrimidine-7-amine-7-amine compounds as CDK (cyclin-dependent kinase) inhibitors and their therapeutic use. The compounds are classified under multiple IPC codes including C07D 487/04 and C07D 519/00, with therapeutic application designated for cancer treatment under A61P 35/00.\n\nPharmaceutical companies and drug manufacturers developing CDK inhibitor therapies should review this patent for freedom-to-operate considerations. The patent is designated across 41 European states including all EU member states, Switzerland, Norway, and other EPC contracting states.